A HERITAGE OF INNOVATION AND LEADERSHIP
Lantheus Medical Imaging, a global leader in developing, manufacturing, selling, and distributing innovative diagnostic imaging agents, is dedicated to creating and providing medical imaging solutions to improve the treatment of human disease.
Our expertise in discovering, developing and commercializing innovative medical imaging agents provides a strong platform from which to bring forward breakthrough tools for the diagnosis and management of disease. Lantheus has a rich heritage and expertise in cardiovascular imaging and nuclear medicine, having pioneered many of the most significant products used in medical imaging.
Our current imaging agents primarily assist in the diagnosis of heart, vascular and other diseases using nuclear imaging, echocardiography and magnetic resonance imaging (MRI) technologies. We have a pipeline of next-generation and first-in-class products using Positron Emission Tomography (PET) and MRI technologies.
Our vision is to be the leading provider of innovative medical imaging solutions to improve human life. We are committed to developing next generation and first-in-class imaging agents to assist physicians in the diagnosis of heart, vascular and other diseases.
With direct operations in the United States, Puerto Rico, Canada and Australia, we have a long and distinguished history of developing and commercializing innovative market-changing products.
Lantheus Medical Imaging Announces Xenon 133 Supply Agreement with
Institute for Radioelements
Agreement Demonstrates Lantheus’ Commitment to Secure Continuous Supply
of Xenon 133 to U.S. Medical Market through 2016 and Beyond
No. BILLERICA, Mass. (January 21, 2015) – Lantheus Medical Imaging, Inc. (Lantheus), a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents, today announced a new strategic agreement with the Institute for Radioelements (IRE) for the future supply of Xenon Xe 133 Gas (Xenon 133). The agreement supports Lantheus’ commitment to ensuring that the medical community has continued reliable access to Xenon 133 to meet the needs of patients. Presently, Lantheus is the only U.S. manufacturer of Xenon 133, which is an inhaled radiopharmaceutical imaging agent used for the evaluation of pulmonary function and for imaging the lungs, as well as the assessment of cerebral blood flow.
click here for the press release
Q3 2014 Lantheus Medical Earnings Conference Call (Live)
Wednesday, November 12, 2014 at 4:30 p.m. ET